We are monitoring the impact of COVID-19 on APAC Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1339
Share on
Share on

Asia Pacific Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode of Administration, End Users, Country (India, China, Japan, Australia, New Zealand, ASEAN Countries and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast | 2020 to 2025

Pulished: February, 2020
ID: 1339
Pages: 132

Asia Pacific Cancer Immunotherapy Market Size (2020 to 2025)

The size of the Cancer Immunotherapy Market in the Asia Pacific was worth USD 15.56 Billion in 2019 and estimated to reach USD 28.92 Billion by the end of 2024 with a growing potential of 13.20 %.

The factors driving the growth of the cancer immunotherapy market are the increasing incidence of cancer, technological advances in therapies, increasing research and development used in cancer treatment, and a wide range of treatments. India and China are significant contributors to APAC, launching new and advanced drugs. In 2012, 6.7 million cancer cases were registered in the APAC region, which is increasing continuously. The specificity and effectiveness of cancer immunotherapy used in breast, skin, and other cancers. During the analysis period, growth in healthcare spending and medical insurance is expected to drive APAC Cancer Immunotherapy Market growth.

The lack of experienced medical professionals has limited this growth of the APAC Cancer Immunotherapy Market. Also, the significant loss of new product development is another factor restraining market growth.

The APAC Cancer Immunotherapy Market is expected to face several challenges throughout the forecast period. The emergence of the latest technologies in the medical sector is likely to bolster the market demand. Increasing disposable income in urban areas is also a factor leveraging the growth of the market. 

The lack of knowledge and awareness are the challenges in the APAC Cancer Immunotherapy Market.

This research report has been segmented & sub-segmented into the following categories:

  • By Type of Therapies: Immune System Modulators, Immune Checkpoint Inhibitors & Monoclonal Antibodies
  • By Area of Therapy: Blood Cancer, Prostate Cancer, Melanoma, Breast Cancer, Lung Cancer, Colorectal Cancer & Other Minor Areas
  • By Country: India, China, Japan, South Korea, Australia & New Zealand, ASEAN countries (ASEAN (Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam, and others) and Rest of APAC)

Regionally, The Asia Pacific region will experience the fastest growth during the forecast period. New advanced immunotherapy drugs are being launched in China and Japan. Numerous clinical trials are underway in these countries/regions. New drug molecules and combination therapies approved by the FDA have been obtained. The approval of new treatments by China and Japan drives the application of immunotherapy in the treatment of cancer. Some market participants such as AstraZeneca, Merck, and Pfizer are investing heavily, expanding the Asia Pacific market.

Chinese Cancer Immunotherapy Market is projected to be the second-largest country for cancer immunotherapy drugs as a result of increasing government assistance, growing economy, and the increasing amount spent on healthcare surge the growth of this region. In 2015, in China, around 4.2 new cases of cancer were recorded. Adoption of sedentary lifestyles and changes in food habits are mainly enhancing the demand of this market to the extent.

Indian Cancer Immunotherapy Market is expected to have a considerable growth rate in cancer immunotherapy drugs market. Advanced technologies in manufacturing drugs, growing patient population, increasing older people, and rising investments from government and other private organizations in the medical field fuel the demand of the market.

Companies leading the APAC cancer immunotherapy Market are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp, Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  2. Asia-Pacific Breast Market By Region, From 2020 to 2025 (USD Billion)
  3. Asia-Pacific Lung Market By Region, From 2020 to 2025 (USD Billion)
  4. Asia-Pacific Melanoma Market By Region, From 2020 to 2025 (USD Billion)
  5. Asia-Pacific Colorectal Market By Region, From 2020 to 2025 (USD Billion)
  6. Asia-Pacific Head & Neck Market By Region, From 2020 to 2025 (USD Billion)
  7. Asia-Pacific Prostate Market By Region, From 2020 to 2025 (USD Billion)
  8. Asia-Pacific Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  9. Asia-Pacific Monoclonal Antibodies Market By Region, From 2020 to 2025 (USD Billion)
  10. Asia-Pacific Checkpoint inhibitors/immune modulators Market By Region, From 2020 to 2025 (USD Billion)
  11. Asia-Pacific Therapeutic cancer vaccines Market By Region, From 2020 to 2025 (USD Billion)
  12. Asia-Pacific Oncolytic virus immunotherapy Market By Region, From 2020 to 2025 (USD Billion)
  13. Asia-Pacific Cytokines Market By Region, From 2020 to 2025 (USD Billion)
  14. Asia-Pacific Adoptive T cell Transfer Market By Region, From 2020 to 2025 (USD Billion)
  15. Asia-Pacific Adjuvant immunotherapy Market By Region, From 2020 to 2025 (USD Billion)
  16. Asia-Pacific Interferons Market By Region, From 2020 to 2025 (USD Billion)
  17. Asia-Pacific Interleukins Market By Region, From 2020 to 2025 (USD Billion)
  18. Asia-Pacific BCG Market By Region, From 2020 to 2025 (USD Billion)
  19. Asia-Pacific Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  20. Asia-Pacific Intravenous Market By Region, From 2020 to 2025 (USD Billion)
  21. Asia-Pacific Oral Market By Region, From 2020 to 2025 (USD Billion)
  22. Asia-Pacific Topical Market By Region, From 2020 to 2025 (USD Billion)
  23. Asia-Pacific Intravesical Market By Region, From 2020 to 2025 (USD Billion)
  24. Asia-Pacific Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  25. Asia-Pacific hospitals Market By Region, From 2020 to 2025 (USD Billion)
  26. Asia-Pacific Clinics Market By Region, From 2020 to 2025 (USD Billion)
  27. Japan Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  28. Japan Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  29. Japan Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  30. Japan Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  31. China Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  32. China Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  33. China Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  34. China Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  35. India Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  36. India Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  37. India Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  38. India Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  39. South korea Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  40. South korea Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  41. South korea Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  42. South korea Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)
  43. Australia Cancer Immunotherapy Market By Application, From 2020 to 2025 (USD Billion)
  44. Australia Cancer Immunotherapy Market By Product Type, From 2020 to 2025 (USD Billion)
  45. Australia Cancer Immunotherapy Market By Mode of Administration, From 2020 to 2025 (USD Billion)
  46. Australia Cancer Immunotherapy Market By End users, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample